At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
PTH(1-34) and Pelvic Fracture Healing - a Randomized Controlled Trial
In Brief
A Phase 2 clinical trial evaluating Teriparatide Prefilled Syringe and Placebo for Osteoporotic Fractures. Completed, enrolled 35 participants across 1 site.
Detailed Summary
In the proposed trial the investigators will recruit women and men \>65 years of age with acute osteoporosis-related pelvic fractures and address 3 specific aims over 3 months of treatment in a placebo controlled double blind study to determine if standard care and teriparatide 20 mcg/day versus placebo for pelvic fractures: 1. Results in earlier evidence of cortical bridging on routine radiographs followed by confirmatory Focus CT, a novel method to reduce radiation exposure from CT scans (primary outcome). 2. Leads to a faster reduction in pain as assessed by both the Numeric Rating Scale and a reduction in the use of narcotics (secondary outcome). 3. Leads more rapidly to improved functional outcome using a short physical performance battery to assess lower extremity function (secondary outcome).
Study Details
Timeline
Interventions
TPTD 20 mcg
Matching placebo as a prefilled syringe with all inactive ingredients